Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
How to Trip Rapid Review
Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)
Step 2: press
Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.
A randomized double-blind placebo-controlled trial of autologous platelet-rich plasma intradermal injections for the treatment of vulvarlichensclerosus. 30639885 2019 02 09 1097-6787 2019 Jan 11 Journal of the American Academy of Dermatology J. Am. Acad. Dermatol. A randomized double-blind placebo-controlled trial of autologous platelet-rich plasma intradermal injections for the treatment of vulvarlichensclerosus. S0190-9622(19)30066-0 10.1016/j.jaad.2018.12.060 Goldstein Andrew T AT Center
MonaLisa Touch Laser for the Treatment of VulvarLichenSclerosus MonaLisa Touch Laser for the Treatment of VulvarLichenSclerosus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. MonaLisa Touch Laser (...) for the Treatment of VulvarLichenSclerosus The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. of clinical studies and talk to your health care provider before participating. Read our for details. ClinicalTrials.gov Identifier: NCT03665584 Recruitment Status : Recruiting First Posted : September 11, 2018 Last Update Posted : November 20, 2018 See Sponsor: Center
Platelet-rich plasma (PRP) for the treatment of vulvarlichensclerosus in a premenopausal woman: A case report The use of platelet-rich plasma (PRP) for the treatment of lichensclerosus (LS) in a 38-year-old premenopausal woman is reported. The diagnosis was confirmed histologically and the symptoms documented using the ICIQ Vaginal Symptoms Questionnaire (ICIQ-VS) and the Female Sexual Function Index (FSFI) questionnaire. PRP was prepared from autologous blood using the Regen Cellular Matrix
Expression of galectin-7 in vulvarlichensclerosus and its effect on dermal fibroblasts Lichensclerosus is a chronic and inflammatory disease. Extensive studies have focused on the epidermis, with the dermis or epidermis-dermis receiving less attention. To investigate the role of galectin-7, a keratinocyte protein, in vulvarlichensclerosus (VLS) and its potential effects on dermal fibroblasts, immunohistochemical staining was performed with VLS tissue samples and normal control samples (...) associated with the galectin-7 treatment concentration. The overexpression of galectin-7 is associated with the progression of VLS in the epidermis, a high concentration of galectin-7 inhibits the viability of the primary vulvar dermal fibroblasts, and stimulates the accumulation of collagen I and collagen III in dermal fibroblast cultures, thus galectin-7 may serve as a drug target during VLS progression.
Diagnosis and Treatment of VulvarLichenSclerosus: An Update for Dermatologists. Vulvarlichensclerosus is an important skin disease that is common in women in their 50 s and beyond; however, it can also affect females of any age, including children. If not treated, it has the potential to cause significant and permanent scarring and deformity of the vulvar structure. In addition, if untreated, it is associated with a 2-6% lifetime risk of malignant squamous neoplasia of the vulva. Lichen (...) sclerosus has been considered a difficult to manage condition; however, both serious complications can potentially be prevented with early intervention with topical corticosteroid, suggesting that the course of the disease can be treatment modified.
Vulvar Neoplasms in 275 Women With Genital LichenSclerosus and Impact of Treatment: A Retrospective Chart Review. 29524285 2018 08 23 1468-3083 32 9 2018 Sep Journal of the European Academy of Dermatology and Venereology : JEADV J Eur Acad Dermatol Venereol Vulvar neoplasms in 275 women with genital lichensclerosus and impact of treatment: a retrospective chart review. e363-e365 10.1111/jdv.14938 Dell E A EA Department of Dermatology, Mayo Clinic, 200 First St SW, Rochester, MN, 55905, USA
Differentiated Vulvar Intraepithelial Neoplasia-like and LichenSclerosus-like Lesions in HPV-associated Squamous Cell Carcinomas of the Vulva. Most human papillomavirus (HPV)-associated vulvar squamous cell carcinomas (VSCCs) originate from high-grade squamous intraepithelial lesions, also named usual type vulvar intraepithelial neoplasia. However, growing evidence suggests that morphologic studies have limitations in predicting HPV status in vulvar lesions. We aimed to evaluate adjacent (...) intraepithelial lesions in a series of DNA HPV-positive VSCCs, focusing on unusual histologic patterns mimicking differentiated vulvar intraepithelial neoplasia (dVIN) or lichensclerosus (LS). We identified 326 DNA HPV-positive VSCC with at least 1 cm of skin adjacent to the invasive tumor and analyzed HPV typing, HPV E6*I mRNA, and p16 immunohistochemistry in all cases. A careful histologic evaluation was conducted. A conclusive association with HPV was based on a positive p16 or HPV E6*I mRNA result
Vulvarlichensclerosus in a prepubertal girl 30443372 2019 02 26 2053-8855 2018 12 2018 Dec Oxford medical case reports Oxf Med Case Reports Vulvarlichensclerosus in a prepubertal girl. omy104 10.1093/omcr/omy104 Rodrigues Alexandra A Paediatrics Department, Hospital Dr. Nélio Mendonça, Funchal, Portugal. Cabral António Jorge AJ Paediatrics Department, Hospital Dr. Nélio Mendonça, Funchal, Portugal. Faria Anabela A Dermatology Department, Hospital Dr. Nélio Mendonça, Funchal, Portugal
Association of Retinoic Acid Receptor β Gene With Onset and Progression of LichenSclerosus-Associated Vulvar Squamous Cell Carcinoma. Molecular alterations in lichensclerosus-associated vulvar squamous cell carcinoma (LS-VSCC) are largely unknown.To determine whether the retinoic acid receptor β (RARβ) tumor-suppressor gene is involved in the onset and/or progression of LS-VSCC.The case-control study, conducted at University-Hospital of Ferrara, Italy, included 20 LS-VSCC (mean [SD] age, 75 (...)  years) and 20 cancer-associated vulvar LS (caVLS; mean [SD] age, 62  years) formalin-fixed embedded tissue specimens, 20 cancer-free vulvar LS (cfVLS), and 20 normal skin fresh specimens from diagnostic biopsies and women surgically treated for nonmalignant skin lesions, respectively. RARβ gene expression and promoter methylation were investigated in LS-VSCC and caVLS adjacent to VSCC specimens, and in cfVLS and normal skin specimens, as controls, by RT-Q real-time polymerase chain
(scleros* or atrophi* or albu* or scleureu* or sclero-atrophi* or vulva* or genita*)).ab,ti. 3. "white spot* diseas*".ab,ti. 4. exp VulvarLichenSclerosus/ 5. "kraurosi* vulva*".ab,ti. 6. (vulva* and (atroph* or dystroph*)).ab,ti. 7. exp Balanitis Xerotica Obliterans/ 8. balaniti* xerotic* oblitera*.ab,ti. 9. "kraurosi* peni*".ab,ti. 10. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 11. Randomized Controlled Trials as Topic/ 12. randomized controlled trial/ 13. Random Allocation/ 14. Double-Blind Method (...) (blind$3 or mask$3)).tw. 29. Placebos/ 30. placebo$.tw. 31. randomly allocated.tw. 32. (allocated adj2 random$).tw. 33. 27 or 28 or 29 or 30 or 31 or 32 34. 26 or 33 35. case report.tw. 36. letter/ 37. historical article/ 38. 35 or 36 or 37 39. 34 not 38 40. 10 and 39 MEDLINE search for case reports 1. exp LichenSclerosus et Atrophicus/ 2. (lichen adj3 (scleros* or atrophi* or albu* or scleureu* or sclero-atrophi* or vulva* or genita*)).ab,ti. 3. "white spot* diseas*".ab,ti. 4. exp VulvarLichen
British Association of Dermatologists' guidelines for the management of lichensclerosus GUIDELINE BJD British Journal of Dermatology British Association of Dermatologists guidelines for the management of lichensclerosus, 2018* F.M. Lewis iD, 1,2 F.M. Tatnall, 3 S.S. Velangi, 4 C.B. Bunker, 5,6 A. Kumar, 7 F. Brackenbury, 8 M.F. Mohd Mustapa 9 and L.S. Exton 9 1 Frimley Health NHS Foundation Trust, Slough SL2 4HL, U.K. 2 St John’s Institute of Dermatology, Guy’s & St Thomas’ NHS Foundation (...) Trust, London SE1 9RT, U.K. 3 West Hertfordshire NHS Trust, Watford WD18 0HB, U.K. 4 University Hospitals Birmingham NHS Foundation Trust, Birmingham B15 2TH, U.K. 5 University College London Hospitals NHS Foundation Trust, University College Hospital, London NW1 2BU, U.K. 6 Chelsea & Westminster NHS Foundation Trust, London SW10 9NH, U.K. 7 King’s College London, London SE1 3ER, U.K. 8 Association for LichenSclerosus and Vulval Health, Brighton, U.K. 9 British Association of Dermatologists, Willan
Therapeutic comparison between treatments for VulvarLichenSclerosus: study protocol of a randomized prospective and controlled trial. Vulvarlichensclerosus (VLS) is a lymphocyte-mediated disease of unknown etiology that can cause intense itching as well stenosis, hindering the evacuation and urination. It can also limit the sex life due to severe local pruritus, pain and dyspareunia (pain during sexual intercourse). The standard treatment for this disease is the use of topical
Clearance in vulvarlichensclerosus: a realistic treatment endpoint or a chimera? According to the current guidelines, the aim of vulvarlichensclerosus (VLS) treatment was to improve symptoms and signs, not to cure.To assess (i) the rate of patients with VLS who achieved complete clearance of symptoms or objective features, or both, with a 12-week pharmacological treatment and (ii) the predictive value of therapeutic response to the demographic and clinical features.We retrospectively
Mometasone furoate in the treatment of vulvarlichensclerosus: could its formulation influence efficacy, tolerability and adherence to treatment? To assess the effectiveness, tolerability, and convenience of the cream formulation of mometasone furoate 0.1% (MMF) in the treatment of active vulvarlichensclerosus (VLS) and to compare the cream with the ointment formulation.The following efficacy parameters were assessed in 27 VLS patients treated with MMF cream for 12 weeks (group A): (i
Development of the Adult VulvarLichenSclerosus Severity Scaleâ€”A Delphi Consensus Exercise for Item Generation To generate a list of items through international expert consensus consisting of both symptoms and clinical signs for inclusion in an adult vulvarlichensclerosus severity scale.This study was carried out as a three-stage Delphi consensus exercise. After an extensive literature review, any items used to determine disease severity in previous clinical trials were compiled (...) for a variety of items for use in an adult vulvarlichensclerosus severity scale that will be further developed and tested. Ideally, this scale will be used in clinical practice and in research to allow for high-quality trials.
Comparison of 5-Aminolevulinic Acid Photodynamic Therapy and Clobetasol Propionate in Treatment of VulvarLichenSclerosus. The aim of this study was to evaluate the effectiveness of 5-aminolevulinic acid photodynamic therapy (ALA-PDT) for the treatment of vulvarlichensclerosus (VLS) and compare its effectiveness with that of clobetasol propionate. Four sessions of topical photodynamic therapy (PDT) were administered at 2-week intervals (n = 20). Clobetasol propionate (0.05%) was used daily
Treatment alternatives for vulvarlichensclerosus: a systematic review and armed based network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files
Platelet Rich Plasma (PRP) for VulvarLichenSclerosus Platelet Rich Plasma (PRP) for VulvarLichenSclerosus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Platelet Rich Plasma (PRP) for VulvarLichen (...) Study Description Go to Brief Summary: Lichensclerosus (LS) is a skin condition of the external genitals (vulva) of women. LS causes vulvar itching, pain, and burning. In addition, LS causes scarring of the vulva which may cause significant sexual dysfunction or pain. Lastly, 4-6% of women with LS will develop vulvar cancer. The current "gold standard" treatment for lichensclerosus is potent steroids creams. When used correctly, steroid creams help to decrease the symptoms of itching and burning
Fractional / Pixel CO2 Laser Treatment of Vulvar Atrophy and LichenSclerosus Fractional / Pixel CO2 Laser Treatment of Vulvar Atrophy and LichenSclerosus - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more (...) . Fractional / Pixel CO2 Laser Treatment of Vulvar Atrophy and LichenSclerosus The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our for details. ClinicalTrials.gov Identifier: NCT03063684 Recruitment Status : Active, not recruiting First Posted : February 24, 2017 Last Update Posted : February 21, 2019 Sponsor: Hadassah Medical Organization Information